
Greek internists are urging health authorities to add tirzepatide, sold commercially as Mounjaro, to the country’s electronic prescription system amid growing concern over its unregulated use for weight loss.
The Professional Union of Internists of Greece warned Friday that the injectable drug, authorized in late 2024 for treating type 2 diabetes and obesity, is currently dispensed with only a handwritten prescription and is not reimbursed by national insurance.
Unlike similar medications such as Ozempic, tirzepatide does not yet require electronic monitoring, making it difficult to track misuse.
Physicians warn that this loophole could encourage unsupervised use by individuals seeking cosmetic weight loss, bypassing proper medical assessment and risking serious side effects including gastrointestinal issues, hypoglycemia, and impaired drug absorption.
The union stressed that effective oversight and patient safety require regulated access and ongoing medical supervision.
Pharmacists have also raised concerns about supply shortages affecting patients with legitimate medical needs, citing similar trends seen with other GLP-1 class drugs.
The state must act swiftly to safeguard public health, the group said, stressing that the uncontrolled availability of powerful medications poses risks not only to individuals misusing them, but also to those who truly need them.